Iván Hernández Dalas: Stereotaxis to acquire Robocath for up to $45M
The next-generation Robocath surgical robot is in use during a first-in-human trial. Stereotaxis has agreed to acquire the technology. | Source: Robocath Stereotaxis announced today that it agreed to acquire surgical robot developer Robocath. The transaction includes an upfront payment of $20 million and additional contingent payments of up to $25 million tied to regulatory and commercial milestones, including FDA clearance of the company’s next-generation robotic technology. “Robocath represents a highly strategic addition to Stereotaxis, amplifying and accelerating our strategy as the leading robotic platform for the broad spectrum of endovascular procedures. By combining our complementary robotic mechanisms, we are creating a uniquely capable platform that expands our reach across interventional medicine,” David Fischel, Stereotaxis chair and CEO, said. “This transaction accelerates our strategy, enhances our technological leadership, provides attractive commercial synergies, o...